Dyne Therapeutics (NASDAQ:DYN) Given “Outperform” Rating at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report published on Tuesday, Benzinga reports. They currently have a $47.00 price target on the stock.

A number of other equities research analysts have also commented on DYN. Stifel Nicolaus upped their price target on Dyne Therapeutics from $35.00 to $41.00 and gave the company a buy rating in a research report on Wednesday, March 6th. Chardan Capital upped their target price on Dyne Therapeutics from $20.00 to $31.00 and gave the company a buy rating in a research report on Friday, March 8th. StockNews.com upgraded Dyne Therapeutics to a sell rating in a research report on Thursday, December 21st. HC Wainwright restated a buy rating and set a $36.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, March 6th. Finally, Piper Sandler upped their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the company an overweight rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $37.43.

Dyne Therapeutics Stock Down 0.4 %

Shares of DYN opened at $28.39 on Tuesday. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $30.27. The business has a 50-day simple moving average of $24.26 and a two-hundred day simple moving average of $15.48. The stock has a market cap of $2.33 billion, a PE ratio of -7.21 and a beta of 0.95.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). On average, equities research analysts expect that Dyne Therapeutics will post -3.23 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In related news, insider Wildon Farwell sold 1,585 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the sale, the insider now directly owns 151,590 shares of the company’s stock, valued at $3,895,863. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Joshua T. Brumm sold 218,536 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $18.51, for a total transaction of $4,045,101.36. Following the completion of the sale, the chief executive officer now directly owns 584,971 shares of the company’s stock, valued at $10,827,813.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Wildon Farwell sold 1,585 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $25.70, for a total value of $40,734.50. Following the transaction, the insider now directly owns 151,590 shares of the company’s stock, valued at $3,895,863. The disclosure for this sale can be found here. Insiders sold a total of 2,165,394 shares of company stock valued at $49,837,369 over the last ninety days. 32.89% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its holdings in shares of Dyne Therapeutics by 49.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,510 shares of the company’s stock worth $39,000 after acquiring an additional 1,155 shares during the period. Royal Bank of Canada boosted its holdings in shares of Dyne Therapeutics by 72.8% in the second quarter. Royal Bank of Canada now owns 5,078 shares of the company’s stock worth $57,000 after acquiring an additional 2,140 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Dyne Therapeutics by 58.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after acquiring an additional 3,092 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Dyne Therapeutics by 95.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock worth $83,000 after acquiring an additional 4,552 shares during the period. Finally, Sphera Funds Management LTD. bought a new position in shares of Dyne Therapeutics in the fourth quarter worth $83,000. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.